-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Positive Sentiment Still Eludes Austar Lifesciences Limited (HKG:6118) Following 29% Share Price Slump
Positive Sentiment Still Eludes Austar Lifesciences Limited (HKG:6118) Following 29% Share Price Slump
The Austar Lifesciences Limited (HKG:6118) share price has fared very poorly over the last month, falling by a substantial 29%. The recent drop completes a disastrous twelve months for shareholders, who are sitting on a 94% loss during that time.
Although its price has dipped substantially, there still wouldn't be many who think Austar Lifesciences' price-to-earnings (or "P/E") ratio of 7.1x is worth a mention when the median P/E in Hong Kong is similar at about 9x. However, investors might be overlooking a clear opportunity or potential setback if there is no rational basis for the P/E.
As an illustration, earnings have deteriorated at Austar Lifesciences over the last year, which is not ideal at all. One possibility is that the P/E is moderate because investors think the company might still do enough to be in line with the broader market in the near future. If you like the company, you'd at least be hoping this is the case so that you could potentially pick up some stock while it's not quite in favour.
Check out our latest analysis for Austar Lifesciences
SEHK:6118 Price Based on Past Earnings September 19th 2022 Want the full picture on earnings, revenue and cash flow for the company? Then our free report on Austar Lifesciences will help you shine a light on its historical performance.Does Growth Match The P/E?
Austar Lifesciences' P/E ratio would be typical for a company that's only expected to deliver moderate growth, and importantly, perform in line with the market.
Taking a look back first, the company's earnings per share growth last year wasn't something to get excited about as it posted a disappointing decline of 56%. However, a few very strong years before that means that it was still able to grow EPS by an impressive 1,216% in total over the last three years. Although it's been a bumpy ride, it's still fair to say the earnings growth recently has been more than adequate for the company.
This is in contrast to the rest of the market, which is expected to grow by 20% over the next year, materially lower than the company's recent medium-term annualised growth rates.
With this information, we find it interesting that Austar Lifesciences is trading at a fairly similar P/E to the market. It may be that most investors are not convinced the company can maintain its recent growth rates.
The Key Takeaway
With its share price falling into a hole, the P/E for Austar Lifesciences looks quite average now. Using the price-to-earnings ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.
We've established that Austar Lifesciences currently trades on a lower than expected P/E since its recent three-year growth is higher than the wider market forecast. There could be some unobserved threats to earnings preventing the P/E ratio from matching this positive performance. At least the risk of a price drop looks to be subdued if recent medium-term earnings trends continue, but investors seem to think future earnings could see some volatility.
Having said that, be aware Austar Lifesciences is showing 2 warning signs in our investment analysis, and 1 of those makes us a bit uncomfortable.
You might be able to find a better investment than Austar Lifesciences. If you want a selection of possible candidates, check out this free list of interesting companies that trade on a P/E below 20x (but have proven they can grow earnings).
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
這個奧星生命科學有限公司(HKG:6118)股價在過去一個月表現非常糟糕,大幅下跌29%。最近的下跌為股東們災難性的12個月畫上了句號,在此期間,他們坐擁94%的損失。
雖然其股價已大幅下跌,但在香港市盈率中值約為9倍的情況下,仍不會有很多人認為奧星生命科學7.1倍的市盈率(即市盈率)值得一提。然而,如果市盈率沒有理性基礎,投資者可能會忽視一個明顯的機會或潛在的挫折。
舉例來説,過去一年,奧星生命科學公司的收入一直在惡化,這根本不是理想的情況。一種可能性是,市盈率是温和的,因為投資者認為,該公司在不久的將來可能仍會採取足夠的措施,與大盤保持一致。如果你喜歡這家公司,你至少會希望情況是這樣的,這樣你就可以在它不太受歡迎的時候買入一些股票。
查看我們對Austar生命科學的最新分析
聯交所:6118基於過去收益的價格2022年9月19日想要了解公司的收益、收入和現金流的全貌嗎?那麼我們的免費金星生命科學的報告將幫助你瞭解它的歷史表現。增長是否與市盈率匹配?
對於一家預計只會實現適度增長,而且重要的是表現與市場一致的公司來説,Austar Lifesciences的市盈率將是典型的。
首先回顧一下,該公司去年的每股收益增長並不是什麼令人興奮的事情,因為它公佈了令人失望的下降56%。然而,在此之前的幾年非常強勁,這意味着它仍然能夠在過去三年中實現令人印象深刻的1216%的每股收益增長。儘管這是一段坎坷的旅程,但公平地説,最近的收益增長對公司來説已經綽綽有餘。
這與其他市場形成對比,後者預計明年將增長20%,大大低於該公司最近的中期年化增長率。
有了這些信息,我們發現有趣的是,Austar Lifesciences的市盈率與市場相當相似。可能是大多數投資者不相信該公司能夠保持最近的增長速度。
關鍵的外賣
隨着其股價跌入低谷,奧星生命科學公司的市盈率現在看起來相當平均。僅僅用市盈率來決定你是否應該出售你的股票是不明智的,但它可以成為公司未來前景的實用指南。
我們已經確定,奧星生命科學目前的市盈率低於預期,因為它最近的三年增長高於更廣泛的市場預測。可能存在一些未被察覺的盈利威脅,阻礙了市盈率與這一積極表現的匹配。至少,如果近期的中期盈利趨勢持續下去,股價下跌的風險看起來會較低,但投資者似乎認為,未來的盈利可能會出現一些波動。
話雖如此,但請注意Austar生命科學公司正在顯示兩個警告信號在我們的投資分析中,其中之一讓我們有點不舒服。
你也許能找到比Austar Lifesciences更好的投資。如果您想要選擇可能的候選人,請查看以下內容免費令人感興趣的市盈率低於20倍的公司名單(但已證明它們可以增加收益)。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧